IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION
申请人:LEBAN Johann
公开号:US20120196861A1
公开(公告)日:2012-08-02
The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
本发明涉及通式(I)的化合物,以及其药用可接受的盐或溶剂,作为抗炎和免疫调节剂。
PYRIDINECARBOXAMIDES, USEFUL-PLANT-PROTECTING COMPOSITION COMPRISING THEM AND PROCESSES FOR THEIR PREPARTION AND THEIR USE
申请人:Ziemer Frank
公开号:US20080269059A1
公开(公告)日:2008-10-30
Compounds of the formula (I), or salts thereof,
in which R
1
to R
4
are as defined in formula (I) of claim
1
are suitable as useful-plant-protecting agents for reducing or preventing harmful effects of agrochemicals on the useful plants and their method of preparation are described.
Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
作者:Rishi G. Vaswani、Victor S. Gehling、Les A. Dakin、Andrew S. Cook、Christopher G. Nasveschuk、Martin Duplessis、Priyadarshini Iyer、Srividya Balasubramanian、Feng Zhao、Andrew C. Good、Robert Campbell、Christina Lee、Nico Cantone、Richard T. Cummings、Emmanuel Normant、Steven F. Bellon、Brian K. Albrecht、Jean-Christophe Harmange、Patrick Trojer、James E. Audia、Ying Zhang、Neil Justin、Shuyang Chen、Jon R. Wilson、Steven J. Gamblin
DOI:10.1021/acs.jmedchem.6b01315
日期:2016.11.10
Polycomb repressive complex2 (PRC2) has been shown to play a major role in transcriptional silencing in part by installing methylation marks on lysine 27 of histone 3. Dysregulation of PRC2 function correlates with certain malignancies and poor prognosis. EZH2 is the catalytic engine of the PRC2 complex and thus represents a key candidate oncology target for pharmacological intervention. Here we report
已显示,通过在组蛋白3的赖氨酸27上安装甲基化标记,多梳抑制复合物2(PRC2)在转录沉默中起主要作用。PRC2功能失调与某些恶性肿瘤和不良预后相关。EZH2是PRC2复合物的催化引擎,因此代表了药理学干预的主要候选肿瘤学靶标。在这里,我们报告了我们基于吲哚的EZH2抑制剂系列的优化,该系列导致了CPI-1205的鉴定,CPI-1205是高效的(生化IC 50 = 0.002μM,细胞EC 50= 0.032μM)和EZH2的选择性抑制剂。当以160 mg / kg BID剂量给药时,该化合物在Karpas-422异种移植模型中显示出强大的抗肿瘤作用,目前处于I期临床试验中。另外,我们公开了与人PRC2复合物结合的抑制剂系列的共晶体结构。
1H-imidazo(4,5-b)pyridine compounds
申请人:Eli Lilly and Company
公开号:US03968116A1
公开(公告)日:1976-07-06
Substituted 1-hydroxy-2-(1,1-difluoroalkyl)-1H-imidazo-(4,5-b)pyridine compounds useful as herbicides; and intermediates useful in the synthesis of these compounds. In addition to exhibiting herbicidal activity, the substituted 1-hydroxy-2-(1,1-difluoroalkyl-1H-imidazo(4,5-b)pyridine compounds are of low mammalian toxicity.
Substituted 1-hydroxy-2-(1,1-difluoroalkyl)-1H-imidazo-(4,5-b)pyridine compounds useful as herbicides; and intermediates useful in the synthesis of these compounds. In addition to exhibiting herbicidal activity, the substituted 1-hydroxy-2-(1,1-difluoroalkyl)-1H-imidazo(4,5-b)pyridine compounds are of low mammalian toxicity.